COST-EFFICACY ANALYSIS OF GEFITINIB EFFICACY IN PATIENTS WITH NON OPERABLE NON SMALL CELL LUNG CANCER

COST-EFFICACY ANALYSIS OF GEFITINIB EFFICACY IN PATIENTS WITH NON OPERABLE NON SMALL CELL LUNG CANCER

Drug treatment of disseminated non small cell lung cancer (NSCLC) is an actual issue today. Both clinical and economic efficacy analysis is needed for optimal therapy selection. We performed economic efficacy assessment of gefitinib (G.) therapy in patients with non operable NSCLC who hase no E...

Full description

Bibliographic Details
Main Authors:	S. A. Protsenko, A. V. Rudakova, F. V. Moiseyenko, E. V. Levchenko, D. E. Matsko, A. О. Ivantsov, I. I. Semenov, A. G. Ievleva, N. V. Mitushkina, A. V. Togo, A. V. Novik, E. N. Imyanitov, V. M. Moiseyenko
Format:	Article
Language:	English
Published:	Bashkir State Medical University 2017-01-01
Series:	Креативная хирургия и онкология
Subjects:	non-small-cell lung cancer gefitinib cost-efficacy analysis
Online Access:	https://www.surgonco.ru/jour/article/view/111

Similar Items

GEFITINIB (IRESSA) IN THE TREATMENT OF BRAIN METASTASES FROM NON-SMALL CELL LUNG CARCINOMA
by: D. R. Naskhletashvili, et al.
Published: (2015-04-01)

Effect of the composition of combined solid lipid particles with gefitinib and a photosensitizer on their size, stability and cytotoxic activity
by: L. L. Nikolaeva, et al.
Published: (2024-07-01)

Pyogenic Granuloma in a Patient on Gefitinib
by: António Fernandes Massa, et al.
Published: (2016-06-01)

Gefitinib for Non-small Cell Lung Cancer: A meta Analysis
by: Jiwu GUO, et al.
Published: (2011-04-01)

A Randomized Clinical Study of Gefitinib and Pemetrexed as Second Line Therapy  for Advanced Non-squamous Non-small Cell Lung Cancer
by: Hongyu DAI, et al.
Published: (2013-08-01)

Clinical Observation of Gefitinib with Pericardial Perfusion for  Advanced Non-small Cell Lung Cancer
by: Xiaomeng WANG, et al.
Published: (2018-01-01)

Response to Gefitinib in Pericardial Effusion Due to Lung Cancer
by: Norihiro Kikuchi, et al.
Published: (2003-01-01)

Efficacy and Safety of Gefitinib Plus Anlotinib for Patients with EGFR Positive Advanced Non-Small-Cell Lung Cancer: A Retrospective Exploratory Study
by: Hu WX, et al.
Published: (2022-04-01)

Pharmacokinetics of gefitinib in elderly patients with EGFR-mutated advanced non-small cell lung cancer: a prospective study
by: Yuta Nio, et al.
Published: (2022-11-01)

Chitosan nanoparticle-mediated co-delivery of shAtg-5 and gefitinib synergistically promoted the efficacy of chemotherapeutics through the modulation of autophagy
by: Yan Zheng, et al.
Published: (2017-04-01)

Multiple Myeloma Emerging after Prolonged Gefitinib Treatment for Non-Small Cell Lung Carcinoma
by: Sian Yik Lim, et al.
Published: (2011-04-01)

Clinical Experience of Gefitinib in the Treatment of 32 Lung Adenocarcinoma Patients with Brain Metastases
by: Jianping XU, et al.
Published: (2015-09-01)

The Mechanism of Gefitinib Resistance Induced by Hepatocyte Growth Factor  in Sensitive Non-small Cell Lung Cancer Cells in Vitro
by: Xianglan XUAN, et al.
Published: (2013-01-01)

Naringin alleviates gefitinib-induced hepatotoxicity through anti-oxidation, inhibition of apoptosis, and autophagy
by: Dan Liu, et al.
Published: (2024-10-01)

Gefitinib facilitates PINK1/Parkin-mediated mitophagy by enhancing mitochondrial recruitment of OPTN
by: Ningning Li, et al.
Published: (2022-09-01)

Optimization of Gefitinib-Loaded Nanostructured Lipid Carrier as a Biomedical Tool in the Treatment of Metastatic Lung Cancer
by: Abdelrahman Y. Sherif, et al.
Published: (2023-01-01)

Glycyrol Alone or in Combination with Gefitinib Is Effective against Gefitinib-Resistant HCC827GR Lung Cancer Cells
by: Shuang Zhao, et al.
Published: (2021-11-01)

EGFR Gene Mutation Statuses in Advanced Non-small Cell Lung Cancer Patients and Their Influence on Effect of Gefitinib
by: Wei ZHONG, et al.
Published: (2012-09-01)

Combined treatment with N‐acetylcysteine and gefitinib overcomes drug resistance to gefitinib in NSCLC cell line
by: Jun Li, et al.
Published: (2020-02-01)

Anticancer Effects of Amlodipine Alone or in Combination With Gefitinib in Non-Small Cell Lung Cancer
by: Bingjie Fu, et al.
Published: (2022-06-01)

Gefitinib and methotrexate to resolve tubal ectopic pregnancy: the GEM3 RCT
by: Moakes Catherine A, et al.
Published: (2023-06-01)

USP22 promotes gefitinib resistance and inhibits ferroptosis in non‐small cell lung cancer by deubiquitination of MDM2
by: Peng Lu, et al.
Published: (2024-11-01)

Combined treatment with silibinin and either sorafenib or gefitinib enhances their growth-inhibiting effects in hepatocellular carcinoma cells
by: Ha Ra Gu, et al.
Published: (2015-03-01)

Analysis of Prognostic Factors of 80 Advanced NSCLC Patients Treated with Gefitinib for more than 6 Months
by: Ling DAI, et al.
Published: (2010-11-01)

Metformin sensitizes hypoxia-induced gefitinib treatment resistance of HNSCC via cell cycle regulation and EMT reversal
by: Yin XT, et al.
Published: (2018-11-01)

Interferon-α reduces the gefitinib sensitivity of human non-small cell lung cancer
by: Chi Pan, et al.
Published: (2016-09-01)

Phenformin alone or combined with gefitinib inhibits bladder cancer via AMPK and EGFR pathways
by: Yanjun Huang, et al.
Published: (2018-07-01)

Critical Appraisal of Gefitinib in the Treatment of Non-Small Cell Lung Cancer
by: Yung-Hung Luo, et al.
Published: (2015-09-01)

c-Met Signaling Pathway Participating in the Gefitinib Resistance of Different Gene Types of Non-small Cell Lung Cancer Cells Induced by HGF In Vitro
by: Xianglan XUAN, et al.
Published: (2013-09-01)

Design of gefitinib-loaded PLGA microspheres via microfluidics for lung cancer
by: Ruohan Huang, et al.
Published: (2023-10-01)

Drug delivery systems of gefitinib for improved cancer therapy: A review
by: Deepak Nagdiya, et al.
Published: (2023-11-01)

Pneumothorax triggered by the combination of gefitinib and amrubicin and treated with endobronchial silicone spigots
by: Fumio Imamura, et al.
Published: (2015-01-01)

Prospective Study on Surface-enhanced Laser Desorption/Ionization Protein Fingerprinting for Diagnosing Gene Polymorphism Leading to Drug Resistance Drift:  Sequential Therapy with a Platinum-based Regimen and Gefitinib  for Non-small Cell Lung Cancer
by: Li’na JI, et al.
Published: (2013-01-01)

Gefitinib: a pharmacoeconomic profile of its use in patients with Non Small Cell Lung Cancer EGFR+
by: Viola Sacchi
Published: (2011-06-01)

Aspartames Alter Pharmacokinetics Parameters of Erlotinib and Gefitinib and Elevate Liver Enzymes in Wistar Rats
by: Hajer AlRasheed, et al.
Published: (2022-11-01)

A phase I/II clinical trial on the efficacy and safety of NKT cells combined with gefitinib for advanced EGFR-mutated non-small-cell lung cancer
by: Wanjun Yu, et al.
Published: (2021-07-01)

The Pharmacometabodynamics of Gefitinib after Intravenous Administration to Mice: A Preliminary UPLC–IM–MS Study
by: Billy Molloy, et al.
Published: (2021-06-01)

Molecular-based choice of cytotoxic therapy for cancer
by: E. N. Imyanitov, et al.
Published: (2022-11-01)

Effect and Mechanism of Gefitinib Inhibition on Non-small Cell Lung Cancer  Radiosensitivity of HCC827 and H358 Cell Lines
by: Ziye GAO, et al.
Published: (2012-06-01)

Dissolution enhancement of Gefitinib by solid dispersion and complexation with β-cyclodextrins: In vitro testing, cytotoxic activity, and tablet formulation
by: Adel F. Alghaith, et al.
Published: (2024-06-01)